Bioprospecting and rational engineering of new L-asparaginase to present a better biopharmaceutical for blood cancer treatment (2019)
- Authors:
- USP affiliated authors: PESSOA JUNIOR, ADALBERTO - FCF ; MONTEIRO, GISELE - FCF ; SILVA, TALES ALEXANDRE DA COSTA E - FCF
- Unidade: FCF
- DOI: 10.4172/2155-952X-C2-116
- Subjects: LEUCEMIA; ENZIMAS
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Journal of Biotechnology and Biomaterials
- ISSN: 2155-952x
- Volume/Número/Paginação/Ano: v. 9, p. 58, 2019
- Conference titles: Global Congress on Biotechnology
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
COSTA-SILVA, Tales Alexandre et al. Bioprospecting and rational engineering of new L-asparaginase to present a better biopharmaceutical for blood cancer treatment. Journal of Biotechnology and Biomaterials. Sunnyvale: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://doi.org/10.4172/2155-952X-C2-116. Acesso em: 30 set. 2024. , 2019 -
APA
Costa-Silva, T. A., Costa, I. M., Agamez-Montalvo, G. S., Pessoa Junior, A., & Monteiro, G. (2019). Bioprospecting and rational engineering of new L-asparaginase to present a better biopharmaceutical for blood cancer treatment. Journal of Biotechnology and Biomaterials. Sunnyvale: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.4172/2155-952X-C2-116 -
NLM
Costa-Silva TA, Costa IM, Agamez-Montalvo GS, Pessoa Junior A, Monteiro G. Bioprospecting and rational engineering of new L-asparaginase to present a better biopharmaceutical for blood cancer treatment [Internet]. Journal of Biotechnology and Biomaterials. 2019 ; 9 58.[citado 2024 set. 30 ] Available from: https://doi.org/10.4172/2155-952X-C2-116 -
Vancouver
Costa-Silva TA, Costa IM, Agamez-Montalvo GS, Pessoa Junior A, Monteiro G. Bioprospecting and rational engineering of new L-asparaginase to present a better biopharmaceutical for blood cancer treatment [Internet]. Journal of Biotechnology and Biomaterials. 2019 ; 9 58.[citado 2024 set. 30 ] Available from: https://doi.org/10.4172/2155-952X-C2-116 - Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer
- Chemogenomic study of gemcitabine using Saccharomyces cerevisiae as model cell—molecular insights about chemoresistance
- Mutant L-asparaginase of Dickeya chrysanthemi (Erwinia chrysanthemi) with better biochemical parameters
- Functional and structural evaluation of the antileukaemic enzyme L-asparaginase II expressed at low temperature by different Escherichia coli strains
- Saccharomyces cerevisiae L-asparaginase 1: rational modifications aiming the modulation of kinetic characteristics over different substrates
- Producing L-asparaginase of Erwinia chrysanthemi improved by synthetic evolution of proteins
- Osmolytes stabilize L-asparaginase II without changing its secondary structure
- Otimização do meio de cultura para a produção de L-asparaginase extracelular em E. Coli BL21 (DE3)
- Evaluation of bacterial expression strains for the production of recombinant L-asparaginase, an antileukemic enzyme from Escherichia coli
- Evaluation of the activity and resistance to proteolytic cleavage of recombinat L-asparaginase obtained by error-prone polymerase chain reaction
Informações sobre o DOI: 10.4172/2155-952X-C2-116 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
